Silence Therapeutics (SLN) Total Current Liabilities (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Total Current Liabilities for 7 consecutive years, with $13.6 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities fell 19.08% to $13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, down 19.08% year-over-year, with the annual reading at $13.6 million for FY2025, 19.08% down from the prior year.
- Total Current Liabilities hit $13.6 million in Q4 2025 for Silence Therapeutics, down from $17.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $25.7 million in Q4 2022 to a low of $13.6 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $18.8 million across 5 years, with a median of $18.3 million in 2025.
- Biggest five-year swings in Total Current Liabilities: crashed 39.46% in 2021 and later rose 25.89% in 2022.
- Year by year, Total Current Liabilities stood at $20.4 million in 2021, then rose by 25.89% to $25.7 million in 2022, then dropped by 14.31% to $22.1 million in 2023, then fell by 23.72% to $16.8 million in 2024, then fell by 19.08% to $13.6 million in 2025.
- Business Quant data shows Total Current Liabilities for SLN at $13.6 million in Q4 2025, $17.4 million in Q3 2025, and $14.8 million in Q2 2025.